English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

In animal models, the incretin hormone GLP-1 affects Alzheimer’s disease (AD). We hypothesized that treatment with GLP-1 or an analog of GLP-1 would prevent accumulation of Aβ and raise, or prevent decline of, glucose metabolism (CMR glc ) in AD. In this 26-week trial, we randomized 38 patients with AD to treatment with the GLP-1 analog liraglutide ( n  = 18), or placebo ( n  = 20). We measured Aβ load in brain with tracer [ 11 C]PIB (PIB), CMR glc  with [ 18 F]FDG (FDG), and cognition with the WMS-IV scale (ClinicalTrials.gov NCT01469351). The PIB binding increased significantly in temporal lobe in placebo and treatment patients (both  P  = 0.04), and in occipital lobe in treatment patients ( P  = 0.04). Regional and global increases of PIB retention did not differ between the groups ( P  ≥ 0.38). In placebo treated patients CMR glc  declined in all regions, significantly so by the following means in precuneus ( P  = 0.009, 3.2 μmol/hg/min, 95% CI: 5.45; 0.92), and in parietal ( P  = 0.04, 2.1 μmol/hg/min, 95% CI: 4.21; 0.081), temporal ( P  = 0.046, 1.54 μmol/hg/min, 95% CI: 3.05; 0.030), and occipital ( P  = 0.009, 2.10 μmol/hg/min, 95% CI: 3.61; 0.59) lobes, and in cerebellum ( P  = 0.04, 1.54 μmol/hg/min, 95% CI: 3.01; 0.064). In contrast, the GLP-1 analog treatment caused a numerical but insignificant increase of CMR glc  after 6 months. Cognitive scores did not change. We conclude that the GLP-1 analog treatment prevented the decline of CMR glc  that signifies cognitive impairment, synaptic dysfunction, and disease evolution. We draw no firm conclusions from the Aβ load or cognition measures, for which the study was underpowered.

frontiers in aging neuroscience

In Alzheimer’s Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial